Drug Profile
MTX 102
Alternative Names: C19-A3 GNP; C19-A3 GNP peptide; FP7 EE-ASI; MTX-102Latest Information Update: 14 Apr 2023
Price :
$50
*
At a glance
- Originator Cardiff University; Midatech
- Developer Biodexa Pharmaceuticals; Cardiff University
- Class Antihypercalcaemics; Immunotherapies; Insulins; Peptide fragments; Peptides; Vaccines
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Type 1 diabetes mellitus
Most Recent Events
- 14 Apr 2023 MTX 102 is still in phase I trials for Type-1 diabetes mellitus (In adolescents, In adults) in United Kingdom and Sweden (Intradermal, Injection)
- 28 Jan 2022 No recent reports of development identified for phase-I development in Type-1 diabetes mellitus(In adolescents, In adults) in Sweden (Intradermal, Injection)
- 28 Jan 2022 No recent reports of development identified for phase-I development in Type-1 diabetes mellitus(In adolescents, In adults) in United Kingdom (Intradermal, Injection)